FTH1P22: A Drug Target / Disease Biomarker (G100462772)
FTH1P22: A Drug Target / Disease Biomarker
FTH1P22 is a protein that is expressed in the plasma cells of individuals with multiple myeloma, a type of cancer that affects the bone marrow. The protein is made by a type of white blood cell called a plasma cell, which is a type of immune cell that produces antibodies to help fight off infections.
One of the things that makes FTH1P22 an interesting drug target is its location. It is expressed in the plasma cells of myeloma cells, which are a type of cancer cell that is derived from white blood cells. This means that a drug that targets FTH1P22 could potentially be used to treat myeloma cells, which could be a major step in the development of new and more effective treatments for this disease.
Another reason for the potential interest in FTH1P22 as a drug target is its structure. FTH1P22 is a protein that is made up of multiple domains, including an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is the part of the protein that is exposed to the outside of the cell, and it is responsible for interacting with other proteins and molecules. The transmembrane domain is the part of the protein that is responsible for spanning the membrane of the cell and interacting with other proteins on the other side of the membrane. The intracellular domain is the part of the protein that is internal to the cell and interacts with other molecules inside the cell.
One of the things that makes FTH1P22 so interesting as a drug target is its ability to interact with other proteins and molecules. Its extracellular domain is thought to interact with a protein called FcgammaR1, which is a protein that is expressed in many different types of cells. FcgammaR1 is also known as CD73, and it is a protein that is involved in the production of various bioactive molecules, including proteins, enzymes, and small molecules.
The transmembrane domain of FTH1P22 is also thought to interact with other proteins and molecules. For example, it is thought to interact with a protein called ALX1, which is a protein that is expressed in many different types of cells, including muscle cells and cancer cells. ALX1 is also known as myostatin, and it is a protein that is involved in the regulation of muscle growth and differentiation.
The intracellular domain of FTH1P22 is also thought to interact with other molecules inside the cell. For example, it is thought to interact with a protein called Pyroptidyl-conjugated protein (PyCP), which is a protein that is expressed in many different types of cells, including cancer cells. PyCP is also known as heat shock protein (HSP), and it is a protein that is involved in the regulation of various cellular processes, including the stress response and protein folding.
In conclusion, FTH1P22 is an interesting protein that is potential drug target in the treatment of myeloma. Its location in the plasma cells and its ability to interact with other proteins and molecules make it an attractive target for drug development. Further research is needed to fully understand the role of FTH1P22 as a drug target in the treatment of myeloma.
Protein Name: Ferritin Heavy Chain 1 Pseudogene 22
The "FTH1P22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTH1P22 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FTH1P24 | FTH1P3 | FTH1P4 | FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP
